ArticleMovement disorders clinical practice2026
Evaluating the Role of α-Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundα-synuclein seeding amplification assay (α-synuclein SAA) development as a diagnostic biomarker for Parkinson's disease (PD) has shown promising results over the past decade. However, the utility of these assays in the prediction of disease progression is unclear.
objectivesTo assess the relationship between α-synuclein SAA and PD-specific clinical outcome measures.
methodsWe extracted longitudinal data on individuals with sporadic PD from the Parkinson's Progression Markers Initiative at baseline and 5 years follow-up. Primary outcome measures included MDS-UPDRS Part III, Montreal Cognitive Assessment (MoCA) and L-dopa equivalent daily dose (LEDD). Secondary outcome measures included REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) question-6 and other non-motor assessments. α-synuclein SAA kinetic parameters were added to linear regression models to assess their impact on model fit.
resultsWe included 279 participants in the final analysis. There was no consistent evidence that α-synuclein SAA parameters at baseline improved our prediction models for MDS-UPDRS Part III, MoCA or LEDD at 5 years. α-synuclein SAA kinetic parameters improved model fit for RBDSQ question-6 and indicated that fast seeding profiles were associated with higher scores.
conclusionsWe did not find evidence of a relationship between α-synuclein SAA and disease progression however α-synuclein SAA was associated with RBDSQ. Further work is needed to understand the factors influencing α-synuclein aggregation kinetics and the role of α-synuclein SAA in disease prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.